Market Research Blog

[194 Pages Report] The global Orthokeratology Market is expected to be worth US$ 58.1 million in 2022, rising to US$ 88.7 million by 2028, at a CAGR of 7.3 percent from 2022 to 2028.

Orthokeratology has been considered to facilitate the elimination of contact lens related vision problems, providing patients with the freedom to experience an active lifestyle.

While this factor will continue to play a pivotal role in growing adoption of Ortho-K lenses, Future Market Insights has discovered a few other factors that are likely to impact the growth of orthokeratology market in near future. In a recently released report, titled “Orthokeratology Market: Global Industry Analysis 2013-2021 and Opportunity Assessment, 2022–2028,” the performance of global market for orthokeratology is assessed for a 10-year period 2022-2028.

Increasing online efforts in patient education and awareness about Ortho-K, coupled with an intensifying rate of success of orthokeratology lenses in recent years, is expected to strengthen the prospects for global orthokeratology market, over the next decade. The market is likely to witness a promising CAGR of 7.4%; whereas, the global revenue is anticipated to reach beyond US$ 88 million by the end of 2028.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3142

While increasing prevalence of myopia stands as a key factor impacting the market growth, several advantages of Ortho-K lenses over the conventional contact lenses have been recognized to be pushing adoption of orthokeratology among sports persons. A few restrictions arising in case of LASIK surgery will also be reportedly responsible for growing inclination for Ortho-K. On the flipside, the adoption of orthokeratology lenses among the myopic patient is less than 0.5%, which is a major factor deterring the growth of the market. In few under developing economies, patient are not able afford the high cost of ortho-k lenses and also the high fees of ophthalmologists and optometrists which will also deter the growth of market to some extent.

Myopia Continues to Remain the Most Influencing Indication, Accounting for a Major Revenue Share

Myopia is expected to remain a key indication driving the demand for orthokeratology, worldwide. With over 70% share of the total market value estimated for 2028, myopia will also provide an extensive scope for innovation opportunities. Hyperopia, followed by astigmatism, will represent the next key indicative factor, which is anticipated to drive market growth over the forecast period.

Get a Customized Scope to Match Your Need, Ask an Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3142

Demand from Optometry Clinics Accounts for a Share that Equates More than Half of the Market Value

Among all distribution channels, optometry clinics will reportedly continue to generate the maximum demand for Ortho-K, accounting for a share of more than 50% to the total market value through 2028. Ophthalmic clinics are expected to hold a decent revenue share throughout the assessment period, whereas hospitals are likely to emerge as the most opportunistic distribution channel.

MEA Still Struggles through Low Awareness Level

North America and Europe, which represent the key regional markets, will reportedly account for a collective value share of around 60% through 2028. Asia Pacific excluding China and Japan is slated for modest growth, whereas MEA will continue to witness sluggish growth rate owing to relatively lower consumer awareness about availability and use of Ortho-K lenses.

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/3142

Key Players :

• The Cooper Companies Inc.
• Euclid Systems Corporation
• Menicon Co., Ltd.
• GP Specialists, Inc.
• TruForm Optics, Inc.
• Art Optical Contact Lens, Inc.
• MiracLens L.L.C.
• Contex, Inc.

Key Segments Covered in Orthokeratology Industry Survey

Orthokeratology Market by Indication:

• Myopia
• Presbyopia
• Hyperopia
• Astigmatism

Orthokeratology Market by Distribution Channel:

• Hospitals
• Optometry Clinics
• Ophthalmology Clinics

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[236 Pages Report] Partnerships between the private sector and public institutions have been the chief agenda of global public health initiatives.

The last few years have witnessed an increase in several private-public partnerships specifically focussing on vaccine provision in developing countries. Partnerships like the International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control (ICG) help magnify the vaccine outreach to remote areas of the world with the maximum need.

Gain complete access to the report @ https://www.futuremarketinsights.com/reports/meningococcal-vaccines-market

The governments of several countries across the globe initiate immunisation programmes periodically and these programmes are backed by global organisations such as UNICEF and WHO and private not for profits like the Global Alliance for Vaccines and Immunization (GAVI).

A classic example of how private-public partnerships are helping boost vaccination programmes across deep regional pockets is Brazil.

In 2010, Ezequiel Dias Foundation, Brazil formed a strategic alliance with Novartis Vaccines & Diagnostics for the sustainable supply of Menjugate MenC vaccines for Brazil’s National Immunization Program. By 2015, Brazil became self-sufficient in the production of the meningococcal C conjugated vaccine for the country’s public vaccination programmes. Such initiatives at the global level are anticipated to support global immunisation goals and at the same time boost growth of the meningococcal vaccines market.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1252

Key Companies Profiled:

• Sanofi Pasteur Inc.
• GlaxoSmithKline Plc
• Wyeth Pharmaceuticals
• Bio-Manguinhos
• Bio-Med Pvt. Limited
• Chongqing Zhifei Biological Products Co., Ltd.
• Hualan Biological Engineering Inc.
• Incepta Pharmaceuticals Ltd.
• Pfizer INC
• Serum Institute of India Pvt. Ltd
• Walvax Biotechnology Co., Ltd.

Factors Leading to Worldwide Adoption of Meningococcal Vaccination Programmes

The global meningococcal vaccines market is expected to be driven by enhanced access to vaccines in low and middle-income countries, growing investments by manufacturers and governments to cope with pandemic meningitis outbreaks, and rapidly growing consumption of meningococcal vaccines bolstered by immunisation alliances and mass vaccination campaigns among others.

Partnerships and alliances between manufacturers and governmental healthcare organisations are facilitating the speedy introduction of vaccines in some of the economically challenged countries of the Middle East and Africa region. Enhanced access to vaccines in under-penetrated global markets is expected to accelerate revenue growth of the global meningococcal vaccines market.

Approval of new vaccines in the U.S and Europe in 2015 and 2017 to treat meningococcal meningitis has revolutionised the global immunisation landscape. This is further boosting the growth trajectory of the global market for meningococcal vaccines.

GlaxoSmithKline to Lead the Global Meningococcal Vaccines Market with About 50% Market Share Recorded in 2017

The global meningococcal vaccines market is highly consolidated, with GlaxoSmithKline and Sanofi together holding about 80% of the global market share in 2017. Pfizer is the third largest company in this market with just under 12% market share in 2017.

Companies are expanding their production capacities through the acquisition of established vaccines production units of other global or local companies.

Sanofi has a huge pipeline of 17 active meningococcal vaccines programmes and is targeting emerging markets; while GlaxoSmithKline has 5 active pipeline programmes for meningococcal vaccines, all of which are in the phase II clinical stage. Addition of the vaccine Bexsero has enabled GlaxoSmithKline to defend its brand against Sanofi’s aggressive portfolio in the paediatric vaccines space.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1252

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 6-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[326 Pages Report] According to a report published by Future Market Insights (FMI), the global gynaecological examination chairs market is expected to witness a CAGR of 6.9% from 2018 to 2028. The market was worth US$ 408.4 Mn in 2017 and is projected to rise to a valuation of US$ 852.3 Mn by the end of 2028.

As a result of the growing demand and expenditure of the consumers, companies are also gearing up in order to take leverage of the arising opportunities and to stay competent in the market. They are strengthening product portfolio by launching novel products with advanced features through product development and acquisitions and mergers. The companies are also concentrating on developing a strong distribution channel and supplier chain in order to expand their presence in the emerging and untapped markets. For instance, in May 2017, Oakworks Inc. announced the introduction of STUDIO, a table designing solution that provides clients with complete flexibility when designing products. Along this line in the same time, the company completed the collaboration with FAMED Medical Solutions. Due to collaboration the company introduce novel iNSPIRITMedical Solutions.

With the growing income of people across the globe, they are willing to pay more for healthcare, the revenue being generated by hospitals is also increasing rapidly. Hospitals and various healthcare facilities are also increasing their spending to enhance the quality of services and their equipment. The proliferating healthcare expenditure is expected to positively impact the gynaecological examination chairs market.

[228 Pages Report] According to the analyst of Future Market Insights (FMI), the leading manufacturers of connected drug delivery devices are focusing collaboration with the software companies to assess the cloud data system in their devices.

The market for connected drug delivery devices is foreseen to witness a stellar growth rate of 25.6% from 2013 to 2028 rising to a valuation of US$ 1,304.7 Mn from US$ 132.2 Mn in 2022.

Moreover, it helps the manufacturer to launch the product more conveniently and to enhance their distribution channel. Manufacturers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly.

The companies operating in the global connected drug delivery devices market are OPKO Health Inc., Bayer AG, 3M Company, West Pharmaceutical Services, Inc., and Teva Pharmaceutical Industries Ltd., among others.

Rapidly evolving technologies, for instance, cloud-based computing models, are enabling the healthcare industry towards a transition to a new architecture.

Cloud technology along with advances in mobility and telepresence solutions is expected to create new unwired business models capable of providing healthcare anywhere.

The use of cloud technology will increase, aided by the proliferation of mobile health applications to collect and send vital signs from wireless and wired remote patient and personal health monitoring devices. Cloud-based platforms and new IT service models will fundamentally change the healthcare business equations and create opportunities for new players to enter the industry.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2755

Growing Demand for Injectable Drug Delivery to Aid Market Growth

The rising preference for injectable drug delivery is anticipated to drive the market for sterile drugs globally. Self-administration of drugs through usage of pre-filled syringes is one of the ways that can help patients to save the fees given to a caregiver. There is an increased demand for large molecule drugs in pre-filled syringes as compared to small molecule drugs in pre-filled syringes

Following this opportunity, the manufacturers are expected to cash in on profits through introduction of smart injectable drug delivery mediums among their portfolio. The progress is expected to be more prominent in the allergic reactions (Anaphylaxis) indication segment. Further, an upsurge in the number of large molecule drugs that need to be manufactured in injectable format is expected to fuel the growth of the market. Likewise, data generated by bioavailability studies is proving to present a definitive relation between pharmacodynamics and pharmacokinetics for such sterile drugs, which is also expected to offer support to the growth of the market.

Mobile applications are also being used for the treatment of patients suffering from Alzheimer, Diabetes, COPD or Asthma. Mobile applications with the use of GPS help to track the patient location. If the patient is travelling away from the home, the caretaker can track the exact location of the patient and also track the consumption of dosage by using mobile application. Most of these applications have been developed for the cloud. Placing the wireless solution on a cloud storage system helps with connectivity issues and makes it easier to communicate across different information regimes.

Limited Knowledge and Adoption Rate among Patients to Hinder Growth Rate

The deployment of connected drug delivery devices is not yet widely promoted within the public health system. This is attributed to the high cost of the product, limited reimbursement, and dearth of awareness among the patients regarding the technology. Moreover, complexity and limited availability of the device further reduces penetration. For instance, interpretation of insulin delivery trend for analysis, is considered to be useful however, because of the complicated user interface, the patients cannot interpret them smoothly. As per the current scenario, such obstacles might directly have an adverse effect on the overall growth of the connected drug delivery devices market.

Ask from Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-2755

Key Segments of Connected Drug Delivery Devices Industry Survey Connected Drug Delivery Devices Market by Product Type:

• Inhalation Devices
• Injectable Devices
  • Handheld Injectable Devices
  • Wearable Injectable Devices

Connected Drug Delivery Devices Market by End User:

• Hospitals
• Clinics
• Home Care

Connected Drug Delivery Devices Market by Application:

• Anaphylaxis
• Cardiovascular
• Diabetes
• Hormone Replacement
• Others

Connected Drug Delivery Devices Market by Technology:

• Bluetooth Drug Delivery Devices
• Near Field Communication Drug Delivery Devices

Connected Drug Delivery Devices Market by Region:

• North America Connected Drug Delivery Devices Market
• Latin America Connected Drug Delivery Devices Market
• Europe Connected Drug Delivery Devices Market
• East Asia Connected Drug Delivery Devices Market
• South Asia & Pacific Connected Drug Delivery Devices Market
• Middle East & Africa (MEA) Connected Drug Delivery Devices Market

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

The global veterinary lasers market is predicted to take a leap from US$ 123.2 Mn (2017) to a value worth US$ 336.5 Mn by the end of 2028. According to the latest market research report published on the global market for veterinary lasers by Future Market Insights, the global veterinary lasers market is projected to register a robust CAGR of 9.7% in terms of value during the forecast period 2018–2028. The report, titled “Veterinary Lasers Market – Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028” provides detailed analysis of the market over the next decade.

Pet Ownership Prevails and Availability of Pet Healthcare Widens

Significant rise in the percentage of pet owners and increasing spending on pets by owners have been the key factors driving the demand for veterinary lasers over the years. Furthermore, a rising number of government and private collaborations to provide quality care to pets will also provide an impetus to the global market for veterinary lasers in near future. Upgradation of veterinary hospitals and clinics that has been creating significant impact on the overall market scenario, coupled with an increasing number of healthcare facilities, will reportedly push the veterinary lasers market a little farther.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-5410

Pet Owners Continue to Look for Non-invasive Treatment Options Through Insurance Cover

Improving implementation of pet insurance coverage is identified to act as a value-driver to market growth during the assessment period. The demand for non-invasive procedures is increasing among pet owners and a majority of them have already accepted laser therapies as a better, efficient, and less painful treatment alternative for pets. This factor will continue to play a crucial role in strengthening the market conditions in upcoming years.

High Costs and Lack of Favorable Reimbursement Policies to Remain Longstanding Challenges

Although probable health risks and expensive costs associated with laser therapies may hamper the penetration of lasers worldwide, Future Market Insights estimates promising growth prospects for the market over 2018-2028. A few other restraints to the growth of market include inadequacy of reimbursement policies in emerging economies, dearth of trained and skilled specialists and professionals, and absence of top notch healthcare infrastructure in certain regions of the world.

Veterinary Lasers Market Segments, Market Dynamics, Market Size, Supply & Demand, Current Trends/Issues/Challenges, Competition & Companies involved, Technology, Pricing, Value Chain: https://www.futuremarketinsights.com/reports/veterinary-lasers-market

Therapeutic and Class 3 Lasers Dominate, Hospitals Continue to Record Maximum Consumption

By product type, therapeutic lasers segment accounted for more than 44% share of the total market revenue in 2017. Future Market Insights estimates continued dominance of this segment and rapid emergence of therapeutic and surgical lasers segment during the forecast period. Based on laser type, class 3 lasers segment is expected to win over class 2 and class 4 lasers segments, accounting for more than 46% share of the market value by 2028 end. Hospitals will reportedly remain the largest end-user of veterinary lasers, capturing over 40% market value share throughout the assessment period.

The Americas Remain the Leading Region, Developing Economies Witness Healthy Growth

The North American market for veterinary lasers is anticipated to continue dominance over all other regional markets throughout the forecast period. With an estimated CAGR of 10.8% in terms of value, North America will possibly reach a value beyond US$ 99 Mn by the end of 2028. Latin America, although a developing country, will register a significant CAGR over the forecast period and remain the second largest as well as second fastest growing regional market for veterinary lasers. The Americas will be followed by the European market, in terms of both value and growth rate. According to the report, emerging economies are presumed to experience robust growth over the projection period.

Our advisory services are aimed at helping you with specific, customised insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-5410

Some of the Key Players Competing in the Global Veterinary Lasers Market, Profiled in the Report:

• Cutting Edge Laser Technologies
• Aesculight Llc
• LiteCure LLC
• Respond Systems, Inc.
• Pivotal Health Solutions
• Laserex Technologies Pty Ltd
• ERCHONIA CORPORATION,
• Technological Medical Advancements, Inc.
• BIOLASE, Inc.

More from FMI’s Healthcare, Pharmaceuticals and Medical devices Market Intelligence:

• Veterinary Ultrasound Scanners Market Veterinary Ultrasound Scanners Market Segmentation By Product Type – Portable/Hand Held, Cart Based Ultrasound Scanner; By Market Size – Veterinary Hospitals, Veterinary Clinics, Animal Breeding and Farms; By Technology – Digital Imaging, Analog Imaging, Others

• Veterinary Vaccines Market Veterinary Vaccines Market Segmentation By Product – Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines; By Disease Application Type – Anaplasmosis, Canine Parvovirus, Foot and Mouth Disease, Newcastle Disease, Distemper Disease, Influenza, PRRS and Others; By Animal Type – Companion Animals, Livestock Animals and Equine; By Distribution Channel – Veterinary Clinics, Veterinary Hospitals, and Others

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

According to a recent report by Future Market Insights (FMI), rising prevalence of pelvic organ prolapse (POP) and stress urinary incontinence (SUI) is expected to boost the growth opportunities for female pelvic implants market. The market is set to reach a valuation of US$ 245 Mn in 2021, rising at a CAGR of 2.8% through the end of 2031.

According to the American Urological Association (AUA/SUFU), the incidence of stress urinary incontinence (SUI) in women was reported to be as high as 49%. The incidence of stress urinary incontinence is high in women with poor or weakened pelvic supports. This disease affects the lives of women to a great extent and is widespread in the older population.

Increasing incidence of vaginal disorders among aged women coupled with the non-availability of other treatment options for SUI and POP will continue increasing the demand in the female pelvic implants market. According to the U.S. FDA, the number of women who have POP is estimated to surge by 46%, to 4.9 million, by 2050.

Get Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3422

However, the low rate of efficacy after pelvic implantation and the problems of pelvic organ prolapse are hampering the growth of the female pelvic implants market.  COVID-19 is anticipated to have a moderately negative impact on the female pelvic implants market due to implementation of lockdown. Supplies and demand were jolted by the massive spread of the infection, which staggered the growth of the female pelvic implants market.

Key Takeaways from Female Pelvic Implants Market Study

• Vaginal sling/tapes demand is anticipated to gain maximum revenue share of more than 68%, rising at an expected CAGR of 2.5% owing to the high demand to treat stress urinary incontinence.
• Hospitals followed by ambulatory surgical centers are leading users of female pelvic implants growing owing to the rising number of POP and SUI patients.
• The U.S. accounts for more than 83% of the North America market, driven by the high incidence of pelvic organ prolapse.
• The U.K.is a leading market in Europe. It is expected to account for nearly 13% of demand registered in Europe by 2031. Implementation of government funded awareness programs will remain a chief growth driver.
• Over 30% of the South Asia market is held by India. Growth in the country is propelled by significant investments in the expansion of healthcare sector.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3422

Post-Marketing Surveillance of Approved Devices Influencing Female Pelvic Implants Demand

An increasing number of manufacturers are continuing to sell their products in the global market despite restrictions by law. After the FDA reclassification of vaginal mesh implants from Class II to Class III medical devices, the FDA has advised 33 manufacturers to conduct 3-year studies to assess impacts of organ damage and other complications of mesh implants.

After assessing the risks, manufacturers can reintroduce their devices and can get pre-market approval from the FDA. This allows manufacturers to re-launch the mesh implants, which is expected to come into the market by 2022.

Who is Winning?

Key players in the market are focusing on strategic collaborations, acquisitions, and expansion. Furthermore, product launches, agreements and research sponsorships are key strategies adopted by manufacturers to strengthen their product portfolios in the female pelvic implants market.

For instance, Coloplast acquired Nine Continents Medical, Inc. in November 2020 and aimed to expand its medical device product portfolio.

The FDA, in 2019 completed its broad evaluation of data associated with the resin used in the production of Boston Scientific’s vaginal mesh through which, the US federal law limits these devices to sale by order of a surgeon.

Want More Insights?

Future Market Insights (FMI) brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global Female Pelvic Implants Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the Female Pelvic Implants Market on basis of product type [Vaginal Mesh Implants, Vaginal Sling/Tape and Vaginal Graft Implants], Indication [Pelvic Organ Prolapse (POP) and Stress Urinary Incontinence (SUI)]. Based on End User [Hospitals, Ambulatory Surgical Centers and Specialized Clinics] across seven major regions.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-3422

Market Taxonomy Product Type

• Vaginal Mesh Implants
• Vaginal Sling
• Vaginal Graft Implants

Indication

• Pelvic Organ Prolapse
• Stress Urinary Incontinence

End User

• Hospitals
• Ambulatory Surgical Centres
• Speciality Clinics

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[276 Pages Report] The global Varicella Zoster Infection Treatment Market is estimated to be worth more than US$ 1.5 billion in 2020, with a CAGR of 4.1% expected to reach US$ 2.0 billion by 2028. According to Future Market Insights, acyclovir will account for more than 55.7% of the overall varicella zoster infection treatment market in 2022.

Future Market Insights (FMI) has published a new report on the varicella zoster infection treatment market titled “Varicella Zoster Infection Treatment Market: Global Industry Analysis 2017 – 2021 and Opportunity Assessment 2022 – 2028.” Varicella zoster infection comprises two main types namely varicella chickenpox and herpes zoster. Varicella is a highly contagious infection with an incubation period of 10–21 days, most commonly 14–16 days, after which characteristic rashes appear.

According to the report, the global varicella zoster infection treatment market is expected to register a 4.2% CAGR from 2017 to 2027. In 2016, the market was worth US$ 1,257.1 Mn and is expected to reach a valuation of US$ 1,969.1 Mn by the end of 2027.